1-Chloroethyl chloroformate (CAS 50893-53-3, C₃H₄Cl₂O₂, relative molecular mass 142.97 g/mol) is supplied under supplier-specific item codes as a pharmaceutical-grade chemical intermediate. The trade descriptor “Pharma Grade API for Tablet / Capsule / Granule / Injection, Oral & Injectable” requires qualification: the substance is not an active pharmaceutical ingredient in a finished dosage form and is not added to tablet blends, capsule powders, granules, or injectable solutions. It is a moisture-sensitive, lachrymatory chloroformate used in the chemical synthesis of active substances that are subsequently processed into oral and injectable dosage forms. Model identifiers are not harmonized across suppliers; the product is specified by CAS number and by the pharma-grade acceptance limits recorded on the certificate of analysis. Typical certificates of analysis report assay by GC-FID of 98.0 % minimum, water by Karl Fischer titration of ≤ 0.05 %, and free chloride of ≤ 0.20 %. The liquid hydrolyzes on contact with water to carbon dioxide, hydrogen chloride, and acetaldehyde via 1-chloroethanol; therefore, processing requires dry inert-gas blanketing and anhydrous solvents.

Physical release data include a boiling range of 150 °C to 153 °C at 101.3 kPa, a density of 1.320 g/cm³ to 1.330 g/cm³ at 20 °C, and a refractive index of 1.421 to 1.423 at 20 °C. The product is a clear, colorless to pale-yellow liquid with a sharp, pungent odor. It is miscible with chlorinated hydrocarbons and ethereal solvents but reacts rapidly with lower alcohols, primary and secondary amines, dimethyl sulfoxide, and aqueous alkali. For pharmaceutical synthesis, the preferred solvents are anhydrous dichloromethane, tetrahydrofuran, or toluene; solvent water content is maintained at ≤ 0.05 % by Karl Fischer before reagent charge. The material is transferred through PTFE, PFA, or Hastelloy C-276 lines under nitrogen or argon; carbon steel and aluminum are incompatible because trace moisture generates hydrochloric acid and promotes corrosion-product contamination of the process stream.

Can a Chloroformate Be Designated an API for Oral or Injectable Drug Product Manufacturing?

The regulatory classification is negative under current pharmacopoeial frameworks. No monograph for 1-chloroethyl chloroformate exists as an active substance in the United States Pharmacopeia, European Pharmacopoeia, or Japanese Pharmacopoeia. Under ICH Q7, the material is an intermediate or reagent, not an active pharmaceutical ingredient. For a finished oral solid dosage form or injectable, the substance should not appear above the residual-solvent or elemental-impurity thresholds defined by ICH Q3C and ICH Q3D. Manufacturers of tablets, capsules, granules, and injectables therefore purchase this material for upstream API synthesis, typically in registered processes where the reagent is consumed and degraded before isolation of the drug substance. The term “Pharma Grade” on the label indicates that the supplier applies GMP-aligned quality systems for change control, batch traceability, and analytical release, but it does not confer API status.

Published handling data require secondary containment and local exhaust ventilation. The transport classification for this chloroformate is UN 2922, Class 8 (6.1), Packing Group II. The classification reflects corrosive and toxic hazards rather than direct pharmaceutical utility. No direct administration route is supported by toxicological monographs. The hydrolysis products hydrogen chloride and acetaldehyde are controlled in pharmaceutical processes: acetaldehyde is listed in ICH Q3C as a Class 2 residual solvent with a permitted daily exposure of 41.0 mg/day and a concentration limit of 410 ppm. Injectable API manufacturers therefore isolate the drug substance after distillation or wiped-film evaporation to reduce acetaldehyde below the applicable limit.

A representative pharma-grade release specification is shown in Table 1. The limits are supplier-specific but are aligned with common analytical procedures for moisture-sensitive chloroformates. No pharmacopoeial monograph establishes the numerical limits; they are controlled by the user’s quality agreement and the registered drug-substance process.

If Selective N-Dealkylation Is Required, α-Chloroethyl Chloroformate Replaces Benzyl Chloroformate

The reagent’s principal application in pharmaceutical synthesis is selective removal of N-alkyl groups from tertiary amines, particularly N-methyl and N-benzyl substituents on alkaloid-derived intermediates. In a typical sequence, the tertiary amine is treated with 1.1 to 1.5 molar equivalents of 1-chloroethyl chloroformate in anhydrous dichloromethane at 0 °C to 25 °C. The quaternized carbamoyl intermediate undergoes chloride-mediated dealkylation; subsequent warming or methanolic cleavage hydrolyzes the resulting carbamate to the secondary amine. This route is selected when hydrogenolysis of benzyl chloroformate-derived Cbz groups is incompatible with other reducible functionalities in the molecule.

Compared with methyl chloroformate (CAS 79-22-1, MW 94.50 g/mol) and ethyl chloroformate (CAS 541-41-3, MW 108.52 g/mol), the 1-chloroethyl derivative is less volatile and more electrophilic at the carbonyl carbon because the α-chloro substituent withdraws electron density. This property permits carbamoylation of hindered tertiary amines under mild conditions. Benzyl chloroformate introduces a Cbz protecting group removed by catalytic hydrogenolysis or strong acid; 1-chloroethyl chloroformate introduces a carbamate intermediate that can be cleaved without hydrogenation, reducing process safety constraints in hydrogen-limited manufacturing lines.

For oral and injectable API synthesis, the impurity profile difference is operationally significant. Ethyl chloroformate-derived ethyl carbamates can remain as stable byproducts if not hydrolyzed; their control in a final injectable requires stringent residual-solvent and genotoxic impurity assessment. 1-Chloroethyl chloroformate degradation products include acetaldehyde and hydrogen chloride. Acetaldehyde is controlled under ICH Q3C as a Class 2 solvent; hydrogen chloride is neutralized during quench. The absence of an ethyl or methyl carbamate pathway is a difference from ethyl chloroformate and methyl chloroformate, which form relatively stable alkyl carbamates under routine workup conditions.

Published data for this specific configuration is limited for some process parameters, but the general reaction profile is documented in synthetic procedures for N-demethylation of opiate alkaloids and related tertiary amines. The reagent excess, solvent, and temperature ranges are those most frequently reported; site-specific optimization is required for each substrate because steric hindrance and amine basicity shift the dealkylation rate.

Controlling Moisture in Glass-Lined Reactor Transfer

The material must be stored in sealed glass or fluoropolymer-lined containers at 2 °C to 8 °C under dry nitrogen or argon. Supplier safety data sheets advise against storage above 25 °C; accelerated decomposition can generate internal pressure through carbon dioxide and hydrogen chloride release. Production-scale glass-lined reactors with nitrogen blanketing and PTFE gaskets are standard. Reactor headspace moisture should be maintained below 100 ppm by purge volume and dry-gas monitoring. Closed-loop charging via dip tubes or vacuum transfer from the supplier container reduces operator exposure and reduces assay loss; supplier technical bulletins report assay loss below 0.5 % with closed transfer, whereas open-port charging under ambient humidity can raise water content above specification and reduce assay by 2 % to 5 %.

Operational boundaries for oral and injectable intermediate synthesis include reaction solvent water content ≤ 0.05 %, quench pH maintained between 6.0 and 8.0 after bicarbonate neutralization, and distillation of residual acetaldehyde below ICH Q3C limits before isolation of the drug substance. The reagent is incompatible with strong bases, primary and secondary amines, lower alcohols, dimethyl sulfoxide, and aqueous media. It should not be combined with amine-based additives during storage or transfer; the resulting reaction forms carbamates, releases heat, and reduces available reagent. The quench exotherm is controlled with jacket cooling at -5 °C to 0 °C during aqueous bicarbonate addition; exceeding 25 °C increases acetaldehyde formation and raises the residual-solvent burden for downstream distillation.

The compound is not suitable for aqueous granulation, hot-melt extrusion, direct compression, or injectable compounding as a component. Any supplier data sheet that lists tablet, capsule, granule, or injection refers to the final dosage forms for which the derived API is intended, not to handling of this chloroformate in finished drug product units. The corrosive and reactive nature precludes safe administration and requires consumption during upstream synthesis.

Comparative Chloroformate Reactivity and Impurity Profiles

The selection of 1-chloroethyl chloroformate over methyl or ethyl chloroformate is driven by the need for selective dealkylation and by process safety. Its higher boiling point reduces vapor-phase operator exposure compared with methyl chloroformate, and its α-chloro substitution accelerates carbamoylation at lower temperatures. Methyl chloroformate is preferred only when stable carbamate protection is desired and the final API does not contain residual methyl carbamate impurities above the limits specified in ICH Q3C. Methyl chloroformate is subject to more restrictive handling because of volatility and acute inhalation toxicity. Benzyl chloroformate requires catalytic hydrogenolysis for Cbz removal, which is incompatible with APIs containing unsaturation, halogenated aromatic rings, or nitro groups. 1-Chloroethyl chloroformate thus occupies a narrow chemical space: it is selected for hydrogenation-sensitive substrates that require tertiary-amine dealkylation without stable alkyl carbamate byproducts.

During scale-up to production batches for tablet and capsule intermediates, the main batch-to-batch variables are hydrolytic degradation during charging and localized overheating during quench. Equipment logs from glass-lined reactors indicate that closed-loop nitrogen transfer maintains assay loss below 0.5 %; manual open-port charging under ambient humidity can raise water content above specification and reduce assay. The quench exotherm is controlled with jacket cooling at -5 °C to 0 °C; exceeding 25 °C increases acetaldehyde formation and raises the residual-solvent burden for downstream distillation. For injectable APIs, the final isolation step typically includes a low-temperature distillation or wiped-film evaporation to remove acetaldehyde to ≤ 410 ppm or lower, in accordance with ICH Q3C Class 2 solvent guidance. The material is not present in the finished oral solid dosage unit or injectable solution; its specifications, handling boundaries, and process limitations apply only to the upstream synthetic steps.